UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 555

Sortiert nach

Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features

Blood, 2012-06, Vol.119 (24), p.5782-5794

2012

Link zum Volltext

Verfügbarkeit prüfen

Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in Mice

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (14), p.3783-3792

2018

Link zum Volltext

Verfügbarkeit prüfen

Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer

Clinical cancer research, 2012-02, Vol.18 (3), p.758-770

2012

Link zum Volltext

Verfügbarkeit prüfen

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302

Molecular cancer therapeutics, 2012-03, Vol.11 (3), p.740-751

2012

Link zum Volltext

Verfügbarkeit prüfen

MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts

PloS one, 2016-05, Vol.11 (5), p.e0155289

2016

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer

PloS one, 2014-12, Vol.9 (12), p.e113586

2014

Link zum Volltext

Verfügbarkeit prüfen

Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models

Clinical cancer research, 2013-12, Vol.19 (23), p.6506-6519

2013

Link zum Volltext

Verfügbarkeit prüfen

Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer Drugs

Journal of medicinal chemistry, 2008-04, Vol.51 (8), p.2412-2420

2008

Link zum Volltext

Verfügbarkeit prüfen

Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro

Molecular cancer therapeutics, 2013-09, Vol.12 (9), p.1763-1773

2013

Link zum Volltext

Verfügbarkeit prüfen

Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models

Cancer biology & therapy, 2016-04, Vol.17 (4), p.371-380

2016

Link zum Volltext

Verfügbarkeit prüfen

A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model

Translational oncology, 2017-10, Vol.10 (5), p.760-765

2017

Link zum Volltext

Verfügbarkeit prüfen

Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition

BMC cancer, 2015-05, Vol.15 (1), p.422-422, Article 422

2015

Link zum Volltext

Verfügbarkeit prüfen

Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies

Antioxidants & redox signaling, 2018-01, Vol.28 (2), p.131

2018

Link zum Volltext

Verfügbarkeit prüfen

TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging

Clinical cancer research, 2015-07, Vol.21 (13), p.2984-2992

2015

Link zum Volltext

Verfügbarkeit prüfen

Retraction: Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy

Oncotarget, 2024-02, Vol.15 (1), p.123-123

2024

Link zum Volltext

Verfügbarkeit prüfen

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug

Blood, 2010-09, Vol.116 (9), p.1524-1527

2010

Link zum Volltext

Verfügbarkeit prüfen

Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study

Neuro-oncology (Charlottesville, Va.), 2018-08, Vol.20 (9), p.1231-1239

2018

Link zum Volltext

Verfügbarkeit prüfen

Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models

Clinical cancer research, 2016-04, Vol.22 (7), p.1687-1698

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2803: Distinct roles of intracellular ROS in cisplatin and evofosfamide cytotoxicity

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2803-2803

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer

Cancer biology & therapy, 2015-03, Vol.16 (3), p.438-449

2015

Link zum Volltext

Verfügbarkeit prüfen

Finding the target after screening the phenotype

Drug Discovery Today, 2005-04, Vol.10 (7), p.513-519

Hart, Charles P.

2005

Link zum Volltext

Verfügbarkeit prüfen

TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules

Cancer chemotherapy and pharmacology, 2012-06, Vol.69 (6), p.1487-1498

2012

Link zum Volltext

Verfügbarkeit prüfen

Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide

Molecular pharmacology, 2019-06, Vol.95 (6), p.638-651

2019

Link zum Volltext

Verfügbarkeit prüfen

Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer

Clinical cancer research, 2017-01, Vol.23 (2), p.536-548

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 555

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(460)
Mit Volltextzugriff
(515)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(541)
Japanisch
(58)
Russisch
(12)

Erscheinungsjahr

n.n

Thema

Science & Technology
(252)
Life Sciences & Biomedicine
(180)
Humans
(169)
Physics
(134)
High Energy Physics - Experiment
(94)
Female
(71)
Animals
(70)
Male
(70)
Biological And Medical Sciences
(67)
Physical Sciences
(50)
Mice
(47)
Medical Sciences
(43)
Adult
(41)
Middle Aged
(39)
Oncology
(34)
Science & Technology - Other Topics
(31)
Multidisciplinary Sciences
(30)
Technology
(27)
Aged
(25)
Physics, Particles & Fields
(25)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features

Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in Mice

Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302

MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts

Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302

Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer

Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models

Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer Drugs

Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro

Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models

A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model

Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition

Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies

TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging

Retraction: Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug

Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study

Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models

Abstract 2803: Distinct roles of intracellular ROS in cisplatin and evofosfamide cytotoxicity

Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer

Finding the target after screening the phenotype

TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules

Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide

Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer

Suchergebnisse filtern